As a potential therapeutic intervention, pharmacological inhibition of PARP1 or SIRT2 demonstrate neuroprotective effects in HD mouse and Drosophila models (Pallos et al., 2008; Cardinale et al., 2015; Paldino et al., 2017). This evidence concerns the gene PARP1 and Huntington disease.